What is RELiZORB?
RELiZORB is a single-use, point-of-care digestive enzyme cartridge that connects in-line with existing enteral pump feeding sets and pump extension sets. RELiZORB is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula.

How does RELiZORB work?
During enteral feeding, RELiZORB works to hydrolyze available fats prior to ingestion of the formula. Enteral formula flows through the RELiZORB cartridge, releasing fatty acids and monoglycerides such as the omega-3 fats DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid), which become available to be absorbed by the patient. Learn more about how RELiZORB works here.

What formulas may be used with RELiZORB?
RELiZORB has been evaluated for use with commercially available enteral formulas and been shown to hydrolyze available fats into absorbable fatty acids and monoglycerides. Enteral formulas containing insoluble fiber should NOT be used with RELiZORB as insoluble fiber may clog the RELiZORB cartridge.

Click here to view a listing of compatible enteral formulas tested with RELiZORB, along with a summary of the hydrolysis achieved.

How much formula can be used with RELiZORB?
A single RELiZORB may be used for up to 500 mL of enteral formula, and up to two RELiZORBs can be used in a day (24-hour period). For enteral tube feeding formula volumes greater than 500 mL and up to 1000 mL, you can follow the Instructions for Use; using one cartridge per 500 mL, or connect two RELiZORBs together in a tandem configuration. The Tandem configuration (two cartridges) is limited to one such use per day. Tandem RELiZORB may also be referred to as “piggy backing”. More information on Tandem RELiZORB can be found here.

What pumps can be used with RELiZORB?
RELiZORB is designed for use with enteral nutrition pump systems with low flow/no flow alarms. RELiZORB is NOT intended for use with gravity feed systems. A detailed listing of pumps, feed sets, and pump extension sets compatible with RELiZORB can be found here.

How was RELiZORB studied?
RELiZORB was evaluated in a multicenter, prospective, randomized, double-blind, placebo-controlled, cross-over study. Patients were ages 5 to 34 with Cystic Fibrosis associated EPI, receiving supplemental enteral nutrition. Clinical results can be found here.

How does RELiZORB connect? Is it easy for my patient?
RELiZORB is easy to use. It simply and quickly connects in-line to the enteral nutrition system after the tube feed pump connector and before connection to the patient. Learn more about how to use RELiZORB here.

Can RELiZORB be re-used?
No. RELiZORB is intended for single-use only. Re-use may result in contamination of the product. If re-used, RELiZORB may not effectively hydrolyze fats. A single RELiZORB may be used for up to 500 mL of enteral formula. For enteral formula volumes greater than 500 mL, install a new RELiZORB after 500 mL of formula has passed through the RELiZORB. A second RELiZORB may be used immediately after the first RELiZORB has been used. Do not use more than two (2) RELiZORBs in a 24-hour period. If less than 500 mL of enteral formula per feeding is used, discard the RELiZORB after use. Learn more about how to use RELiZORB here.

What is iLipase?
Inside the RELiZORB cartridge is the digestive enzyme lipase, which is covalently bound and immobilized to small white beads. This proprietary lipase-bead complex is called iLipase. The iLipase is retained within the RELiZORB cartridge by two filters as enteral formula flows through RELiZORB, and it is not ingested by the patient.

Why is lipase the enzyme used in RELiZORB? Why not amylase and/or protease?
RELiZORB was designed exclusively to address the unmet need of patients on supplemental enteral nutrition who cannot properly hydrolyze, or digest, available fats and therefore may be unable to absorb these vital nutrients.

Of the digestive enzymes lipase, amylase, and protease, lipase hydrolyzes fats while amylase acts on starches and protease acts on proteins. Digestion of proteins and starches is not exclusively dependent on enzyme released by the pancreas,1 whereas fats remain mostly unchanged until they reach the small intestine and interact with pancreatic lipase. Since pancreatic lipase accounts for up to 90% of fat digestion, fat may be the most poorly absorbed macronutrient relative to carbohydrates and proteins.

Therefore, lipase is the enzyme used in RELiZORB. But there’s more to the story. Certain lipases hydrolyze long-chain triglycerides (LCTs), which are difficult to digest. Like human pancreatic lipase, the lipase chosen for use in RELiZORB is intended to selectively cleave triglycerides at the sn-1 and sn-3 positions, but without the need for co-lipase. The lipase in RELiZORB has optimal activity at the pH of enteral formulas.

RELiZORB is designed to mimic the function of pancreatic lipase. RELiZORB hydrolyzes available fats from their triglyceride form into their absorbable form, such as omega-3 fats and monoglycerides, to deliver more absorbable calories from enteral formulas.

Can medications be administered through RELiZORB?
No. Medications should not be administered through the RELiZORB cartridge. Do not add medications to the enteral feed line in between the pump and RELiZORB (before RELiZORB). The passage of medications through RELiZORB may adversely affect the medications or the ability of RELiZORB to hydrolyze fats. If medications, saline flushes, or other non-enteral formula materials are to be added, they must be introduced AFTER RELiZORB (ie, between RELiZORB and the patient). They may be added to the side port of a Y-connector extension set located between the RELiZORB and the patient. Learn more about using RELiZORB here.

Whom should I contact if I have more questions on RELiZORB or would like more information?
Just contact RELiZORB Support Services at 1-844-632-9271 and a helpful professional will be standing by, ready to assist.

Close

This information is intended for
US healthcare professionals

Close
Close

You are now leaving the RELiZORB
product website to view the
Alcresta Therapeutics corporate website.